Understanding how a specific protein affects T cell activation in the immune response.
Function of Siglec 5 in T cell activation.
This study is looking at how a protein called Siglec 5 affects the immune response in T cells, especially when fighting off Group B Streptococcus infections, to help improve treatments for vulnerable groups like newborns.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project ID | NIH-10665549 on NIH RePORTER |
What this research studies
This research investigates the role of Siglec 5, a protein found on certain immune cells, in the activation of T cells, which are crucial for the body's immune response. By examining how Siglec 5 interacts with Group B Streptococcus (GBS), the researchers aim to uncover mechanisms that could lead to better understanding and treatment of infections, particularly in vulnerable populations like newborns. The study employs biological assays to analyze immune responses and cellular interactions, providing insights into how GBS can evade the immune system. This research is particularly focused on the differences in immune responses between infants and adults.
Who could benefit from this research
Good fit: Ideal candidates for this research include pregnant women who may be carriers of Group B Streptococcus and their newborns.
Not a fit: Patients who are not pregnant or do not have any connection to Group B Streptococcus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for preventing and treating infections caused by Group B Streptococcus, particularly in newborns.
How similar studies have performed: Previous research has shown that understanding immune modulation by pathogens can lead to significant advancements in treatment, indicating potential success for this approach.
Where this research is happening
Maywood, United States
- Loyola University Chicago — Maywood, United States (Active)
Researchers
- Principal investigator: Iwashima, Makio — Loyola University Chicago
- Study coordinator: Iwashima, Makio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.